Filing summary
Reporting period: Quarter ended March 31, 2015. The filing identifies the registrant as Zaxis International Inc.; the request metadata names Quantum X Labs Inc. The filing also refers to Emerald Medical Applications Corp. as the company’s former name, while describing Emerald Medical Applications Ltd. as a separate merger counterparty.
Business context and financial results
Zaxis reported no business operations and no revenue in either the first quarter of 2015 or the comparable 2014 quarter. Its stated objective was to pursue a business combination, including a proposed reverse merger with Israeli medical-technology company Emerald Medical Applications Ltd., which develops melanoma detection and diagnostic technology.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $233,936 | $7,750 |
| Net loss | $236,947 | $10,121 |
| Basic loss per share | $0.05 | $0.01 |
| Cash used in operations | $241,436 | $2,500 |
| Cash from financing activities | $795,000 | $2,500 |
The 2015 operating expenses included $190,000 expensed for advances to the merger counterparty because collectability was not reasonably assured, $43,936 of general and administrative expense, and $3,011 of interest expense. With no revenue, the filing provides no meaningful revenue or gross-profit margin measures.
Financial position, liquidity, and financing
- At March 31, 2015, cash and total assets were $554,564, compared with $1,000 at December 31, 2014. Current liabilities were $157,535 and long-term notes payable were $37,375. The balance sheet therefore implies positive working capital of $397,029, although the notes state that the company had negative working capital.
- Financing included $780,000 from a unit sale and $15,000 from issuance of a non-convertible note. The unit sale covered 2,052,000 units at $0.40 each, each consisting of one common share and one warrant exercisable at $0.80. The proceeds were recorded as stock payable because shares were to be issued after the reverse merger was completed.
- Current liabilities included $120,979 of advances payable and $36,556 of accrued interest. The filing reports 4,550,602 common shares issued and outstanding at March 31 and May 14, 2015.
- Two $90,000 and $100,000 advances to Emerald were due 90 days after issuance and carried 1% interest. The filing says Emerald’s ability to repay as a standalone company was highly doubtful if the merger did not close.
- Subsequent to quarter-end, on April 21, 2015, the company repaid the $22,375 December 2014 note and the remaining $15,000 January 2015 note; the stated interest on the latter was waived.
Changes, outlook, and risks
The net loss rose to $236,947 from $10,121, principally reflecting the $190,000 expense for advances to Emerald and higher general and administrative costs. Operating cash use increased to $241,436 from $2,500; the unit financing was the principal source of the quarter’s cash increase.
A December 30, 2014 non-binding MOU contemplated a reverse merger, subject to a definitive agreement and a raise of $800,000 from investors. Emerald’s holders were to receive 45% of the post-closing fully diluted common stock, with up to an additional 21% tied to milestones. The company reported $780,000 of unit proceeds during the quarter, but the filing does not clearly confirm that the definitive agreement was signed or that the merger closed. Management had expected the agreement in the first quarter of 2015.
The company stated that it had no revenue, limited resources, and substantial doubt about its ability to continue as a going concern; additional financing was described as necessary. Management said it believed its efforts to obtain equity financing could provide an opportunity to continue. Risks include failure to complete the merger or raise sufficient capital, potential inability to repay the Emerald advances, dilution or a change of control from share issuance, and constraints on obtaining future financing. Disclosure controls and procedures were reported as ineffective as of March 31, 2015. The filing reported no legal proceedings.
Important facts for investors to verify
- Whether a definitive Emerald merger agreement was executed, the transaction closed, or the proposed $800,000 financing condition was satisfied.
- The collectability and repayment status of the $190,000 advanced to Emerald, including the stated 90-day maturities.
- The conflicting working-capital descriptions: the balance-sheet figures imply positive working capital, while the notes say it was negative.
- The MD&A gives December 31, 2014 current liabilities as $163,874, while the balance sheet reports $163,784; confirm the correct amount.
- How and when the $780,000 of stock payable was converted into issued shares and warrants, and the resulting dilution and ownership structure.
- Management’s plans to address the going-concern uncertainty and ineffective disclosure controls.